Biomea Fusion, Inc. (BMEA) Stock

Biomea Fusion, Inc. (BMEA) is a Healthcare stock trading at $1.17 (as of 2026-06-18), with a market capitalization of $99.05M and a trailing P/E of -2.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biomea Fusion, Inc. is a biopharmaceutical company developing covalent small-molecule drugs for genetically defined cancers and metabolic diseases. Its pipeline includes BMF-219, an orally available covalent inhibitor of menin.

Valuation — source: SEC EDGAR (first-party)
Price$1.17
Market Cap$99.05M
P/E Ratio-2.1
EV / EBITDA-0.6
Price / Book4.52
DCF Value (model)$-15.79
DCF Upside vs Price-1449.6%
Profitability & Growth — source: SEC EDGAR
Return on Equity-240.1%
Current Ratio4.98
Valuation vs Sector & Industry
Stock P/E-2.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-110.2%
vs Industry-112.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($13.48M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael J. Hitchcock
Employees79
CountryUS
IPO Date2021-04-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Cardiol Therapeutics Inc. (CRDL)
  • Equillium, Inc. (EQ)
  • Annovis Bio, Inc. (ANVS)
  • eXoZymes, Inc. (EXOZ)
  • Entera Bio Ltd. (ENTX)
  • Scilex Holding Company (SCLX)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Century Therapeutics, Inc. (IPSC)
BMEA earnings history · BMEA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.